Inicio>>Signaling Pathways>> Tyrosine Kinase>> PDGFR>>PDGFRα kinase inhibitor 1

PDGFRα kinase inhibitor 1

Catalog No.GC65366

PDGFRα El inhibidor de cinasa 1 es un inhibidor de cinasa de PDGFRα tipo II altamente selectivo con IC50 de 132 nM y 6115 nM para PDGFRα y PDGFRβ, respectivamente.

Products are for research use only. Not for human use. We do not sell to patients.

PDGFRα kinase inhibitor 1 Chemical Structure

Cas No.: 2209053-93-8

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
406,80 $
Disponible
1mg
143,00 $
Disponible
5mg
315,00 $
Disponible
10mg
495,00 $
Disponible
25mg
891,00 $
Disponible
50mg
1.485,00 $
Disponible
100mg
2.250,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

PDGFRα kinase inhibitor 1 is a highly selective type II PDGFRα kinase inhibitor with IC50s of 132 nM and 6115 nM for PDGFRα and PDGFRβ, respectively[1].

PDGFRα kinase inhibitor 1 (CHMFL-PDGFR-159, Compound 15i) exhibits weak inhibition to DDR1 kinase (IC50: 2462±126 nM)[1].

[1]. Wang Q, et al. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia. Eur J Med Chem. 2018 Apr 25;150:366-384.

Reseñas

Review for PDGFRα kinase inhibitor 1

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PDGFRα kinase inhibitor 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.